Compare Citius Pharmaceuticals Inc (CTXR) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Manulife Financial Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Manulife Financial Corporation trades at $41.3 (market cap $68.68B). The key difference: Manulife Financial Corporation is far larger — about 4691.3× Citius Pharmaceuticals Inc's market cap, and Manulife Financial Corporation pays a 3.2% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MFC | |
|---|---|---|
Market Cap | $14.64M | $68.68B |
Sector | Health | Financials |
52-Week High | $1.82 | $41.69 |
52-Week Low | $0.53 | $29.90 |
Enterprise Value | $10.86M | $65.24B |
Dividend Yield | — | 3.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Manulife Financial (MFC) trades at $41.29, unchanged on the day, near its 52-week high. The stock shows a bullish technical signal with strong moving averages, while fundamentals reveal steady revenue growth to $53.01B in 2025 and a net income margin of 12.07%. Recent Q1 2026 earnings missed expectations, but analyst consensus remains positive with 57% buy ratings. Key developments include a dividend payment and AI partnership expansions.
Outlook is cautiously optimistic with growth driven by Asia operations and AI initiatives, but risks include Q1 earnings miss and regulatory scrutiny. Valuation at P/E 16.89 and P/B 2.17 appears reasonable. Investors should monitor execution on earnings recovery and wealth management flows amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
